Holen Sie sich die Stockscreener-App
10.90
0.27%
-0.03
Handel nachbörslich:
10.90
Schlusskurs vom Vortag:
$10.93
Offen:
$11.11
24-Stunden-Volumen:
1.36M
Relative Volume:
1.34
Marktkapitalisierung:
$916.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.17M
KGV:
-20.72
EPS:
-0.526
Netto-Cashflow:
$-35.14M
1W Leistung:
-6.20%
1M Leistung:
-23.24%
6M Leistung:
-25.80%
1J Leistung:
+54.83%
1-Tages-Spanne:
$10.64
$11.11
1-Wochen-Bereich:
$10.64
$12.42
52-Wochen-Spanne:
$6.39
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Firmenname
Corvus Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 900-4520
Adresse
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
10.90 | 977.49M | 0 | -44.17M | -35.14M | -0.526 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | Goldman | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-01-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-18 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-05-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-05-29 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-04-18 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
One drug is now in trials for four conditions, including a skin disease. - Stock Titan
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In? - Yahoo! Finance Canada
Corvus Pharmaceuticals at cantor global healthcare: pipeline bets widen By Investing.com - Investing.com South Africa
Trial Results Published Could Be A Game Changer For Corvus Pharmaceuticals (CRVS) - simplywall.st
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference - marketscreener.com
A biotech company's live healthcare talk is set for Sept. 10. Its webcast stays online 90 days. - Stock Titan
Corvus Pharmaceuticals Inc. (CRVS) Peer Comparison – Compare with Others - valueresearchonline.com
CRVS Q2 2026 Earnings: Wider-Than-Expected Loss Reflects Continued Clinical-Stage InvestmentManagement Guidance Update - careplusvn.com
Corvus Pharmaceuticals (CRVS) Declines 3.8% to $14.16 as Stock Tests Key Support at $13.45NHNL Divergence - vinanet.vn
CRVS Q2 2026 Earnings: Wider-than-Expected Loss Sends Shares Down 3.8%EBITDA Analysis - dars.gov.et
Corvus Pharmaceuticals Publishes Blood Data Showing Soquelitinib Activity in T Cell Lymphoma and Supporting Ongoing PTCL, Atopic Dermatitis Trials - quiverquant.com
Corvus Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CRVS - TradingView
Blue Owl Capital Holdings LP Takes Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors (CRVS)? - simplywall.st
637,500 Shares in Corvus Pharmaceuticals, Inc. $CRVS Bought by DCF Advisers LLC - MarketBeat
Corvus (CRVS) Q2 2026 Results: The EPS Result Is Below Expectation; Market Response: The Stock Records a 3.84% Increase in the Current UpdateFinancial Health Score - vinanet.vn
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting - Yahoo Finance
BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView
Corvus Pharmaceuticals (CRVS) Reports A Wider Loss, Is The Stock Still Cheap? - Sahm
CRVS Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Cash BurnGrowth Acceleration Report - dars.gov.et
Corvus Pharmaceuticals Stock Price Forecast. Should You Buy CRVS? - StockInvest.us
Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value (NASDAQ:CRVS) - Seeking Alpha
HC Wainwright Issues Negative Estimate for CRVS Earnings - MarketBeat
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
HC Wainwright Brokers Decrease Earnings Estimates for CRVS - MarketBeat
The Manufacturers Life Insurance Company Buys 84,282 Shares of Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement - Seeking Alpha
Corvus Pharmaceuticals (CRVS) Pulls Back 3% as Biotech Volatility PersistsDip Buy Trade - dars.gov.et
Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss? - Sahm
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Corvus Pharmaceuticals Loss Widens to $18 Million as Soquelitinib Trial Costs Soar - finance.biggo.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Down After Earnings Miss - MarketBeat
State Street Corporation (NYSE: STT) discloses 5.3% ownership in Corvus Pharmaceuticals - Stock Titan
Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRVS SWOT Analysis: Financial Losses and Growth Potential Revealed in 10-Q Filing - GuruFocus
Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ... - Yahoo Finance
Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Corvus Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Corvus posts wider Q2 2026 loss as trials advance - Investing.com
Corvus Eczema Trial Is Expected to Enroll About 200 Patients - stocktitan.net
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Corvus Pharmaceuticals 2Q 2026: Net income $(17.96)M, EPS $(0.19) — 10-Q Summary - TradingView
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Corvus Pharmaceuticals earnings up next as trial progress eyed By Investing.com - Investing.com Nigeria
Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Corvus Pharmaceuticals Inc-Aktie (CRVS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MILLER RICHARD A MD | President and CEO |
May 18 '26 |
Buy |
12.04 |
6,932 |
83,453 |
1,195,035 |
| Thompson Peter A. | Director |
Jan 28 '26 |
Option Exercise |
5.33 |
210,000 |
1,119,374 |
210,000 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):